Q1 EPS Estimate for RenovoRx Raised by Analyst

Key Points

• Ascendiant raised its Q1 2027 EPS estimate for RenovoRx to a loss of $0.06 per share from a projected loss of $0.07; its Q4 2027 estimate is a loss of $0.03 per share.
• RenovoRx’s latest quarter posted a loss of $0.07 per share, missing the $0.06 consensus estimate, while revenue of $1.07 million slightly exceeded expectations.
• Analysts’ consensus rating is Moderate Buy, with a consensus price target of $8.50. State Street increased its stake by 501.6% in the third quarter.

RenovoRx, Inc. (NASDAQ:RNXT - Free Report) - Research analysts at Ascendiant Capital Markets lifted their Q1 2027 earnings estimates for shares of RenovoRx in a research note issued to investors on Saturday, November 7th. Ascendiant Capital Markets analyst E. Woo now expects that the company will post earnings per share of ($0.06) for the quarter, up from their prior forecast of ($0.07). The consensus estimate for RenovoRx's current full-year earnings is ($0.28) per share. Ascendiant Capital Markets also issued estimates for RenovoRx's Q4 2027 earnings at ($0.03) EPS.

A number of other brokerages have also weighed in on RNXT. Wall Street Zen lowered RenovoRx from a "hold" rating to a "sell" rating in a research report on Monday. Weiss Ratings raised RenovoRx from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Wednesday, September 2nd. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $8.50.

RenovoRx Stock Performance

Shares of NASDAQ RNXT opened at $1.22 on Thursday. RenovoRx has a 52-week low of $0.70 and a 52-week high of $2.59. The firm has a market capitalization of $58.87 million, a price-to-earnings ratio of -3.94 and a beta of 1.12. The stock has a 50 day moving average price of $1.50 and a 200 day moving average price of $1.11.

RenovoRx (NASDAQ:RNXT - Get Free Report) last issued its earnings results on Thursday, November 5th. The company reported ($0.07) EPS for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.01). RenovoRx had a negative return on equity of 133.49% and a negative net margin of 469.02%. The company had revenue of $1.07 million during the quarter, compared to the consensus estimate of $1.06 million.

Hedge Funds Weigh In On RenovoRx

A hedge fund recently raised its position in RenovoRx stock. State Street Corp boosted its stake in shares of RenovoRx, Inc. (NASDAQ:RNXT - Free Report) by 501.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 314,636 shares of the company's stock after buying an additional 262,332 shares during the period. State Street Corp owned 0.65% of RenovoRx worth $491,000 as of its most recent filing with the Securities & Exchange Commission. 3.10% of the stock is currently owned by institutional investors.

About RenovoRx

RenovoRx, Inc. is a clinical-stage biopharmaceutical company developing targeted treatments for solid tumors. The company's approach is based on its Trans-Arterial Micro-Perfusion (TAMP) platform, which is designed to deliver chemotherapy directly into tumor tissue through the arterial system while limiting exposure to surrounding healthy tissue. RenovoRx's lead investigational product, RenovoCath, is a localized drug-delivery system intended to support the administration of anticancer therapies to tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.